Series E round led by Morgan Health addresses cancer care gaps.
Tech Funding News states that Thyme Care raised more than $125 million in a Series E round. The round was led by Morgan Health, the employer-healthcare investment arm of J.P. Morgan Chase. The company’s valuation doubled to over $2 billion in under a year. The funding targets gaps in cancer care. The details appear in the publication’s report and its associated post on X.
72
1 post, first seen 3d ago
Series E round led by Morgan Health addresses cancer care gaps.
Tech Funding News states that Thyme Care raised more than $125 million in a Series E round. The round was led by Morgan Health, the employer-healthcare investment arm of J.P. Morgan Chase. The company’s valuation doubled to over $2 billion in under a year. The funding targets gaps in cancer care. The details appear in the publication’s report and its associated post on X.
Tech Funding News@TFNBreakingNews🩺 @ThymeCares has raised more than $125 million in Series E funding, roughly doubling its valuation to over $2 billion in less than a year. @MorganHealth, @JMorganchase’s employer-healthcare investment arm, led the round. @CVSHealth Ventures and @Humana returned as strategic…
Tech Funding News@TFNBreakingNews🩺 @ThymeCares has raised more than $125 million in Series E funding, roughly doubling its valuation to over $2 billion in less than a year. @MorganHealth, @JMorganchase’s employer-healthcare investment arm, led the round. @CVSHealth Ventures and @Humana returned as strategic…
